Report of Foreign Issuer (6-k)
February 22 2017 - 9:44AM
Edgar (US Regulatory)
FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
period ending
22 February
2017
GlaxoSmithKline
plc
(Name
of registrant)
980
Great West Road, Brentford, Middlesex, TW8 9GS
(Address of
principal executive offices)
Indicate by check
mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate by check
mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange
Act of 1934.
Yes
No x
GlaxoSmithKline
plc (the '
Company
')
GlaxoSmithKline
plc
(the
Company
)
GlaxoSmithKline
plc (the
'
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.0000
|
13,284
(Deferred)
|
|
|
£0.0000
|
4,428
(Matching)
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
17,712
£0.0000
|
e)
|
Date
of the transaction
|
2017-02-21
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 21 February 2017 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3575
|
6,369
(Deferred)
|
|
|
£16.3575
|
2,124
(Matching)
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
8,493
£16.3575
|
e)
|
Date
of the transaction
|
2017-02-21
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr S A Hussain
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.0000
|
9,743
(Deferred)
|
|
|
£0.0000
|
3,248
(Matching)
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
12,991
£0.0000
|
e)
|
Date
of the transaction
|
2017-02-21
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr S A Hussain
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 21 February 2017 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4650
|
4,234
(Deferred)
|
|
|
£16.4750
|
1,412
(Matching)
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
5,646
£16.4675
|
e)
|
Date
of the transaction
|
2017-02-21
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr P J T Vallance
|
b)
|
Position/status
|
President, R&D
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.0000
|
26,863
(Deferred)
|
|
|
£0.0000
|
8,954
(Matching)
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
35,817
£0.0000
|
e)
|
Date
of the transaction
|
2017-02-21
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr P J T Vallance
|
b)
|
Position/status
|
President, R&D
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 21 February 2017 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3575
|
12,879
(Deferred)
|
|
|
£16.3575
|
4,294
(Matching)
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
17,173
£16.3575
|
e)
|
Date
of the transaction
|
2017-02-21
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
22, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024